4-Methyl-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-3-yl)piperidine

Catalog No. :
ACUSYY343
CAS No. :
2223040-00-2
Molecular Formula :
C16H26BNO3
Molecular Weight :
291.20

IUPAC Name:4-methyl-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-3-yl)piperidine

4-Methyl-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-3-yl)piperidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-Methyl-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-3-yl)piperidine
IUPAC Name4-methyl-1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-3-yl)piperidine
Molecular FormulaC16H26BNO3
Molecular Weight291.20
SMILESCC(CC1)CCN1C2=COC(B3OC(C)(C)C(C)(C)O3)=C2
InChI KeyJQRNFVLLNFCYQO-UHFFFAOYSA-N
Synonym4-(4-Methylpiperidin-1-yl)furan-2-boronic acid pinacol ester;Piperidine, 4-methyl-1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-furanyl]-
CAS No.2223040-00-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACUSYY343 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUSYY343 route product structure diagram
    ACUSYY3432223040-00-2
Inquiry

2. ACUSYY343 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUSYY343 route product structure diagram
    ACUSYY3432223040-00-2
Inquiry

Comments (0)